Author

C. Gainza

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Approach:deep learning· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

J. E. Crowe· 4 shared E. Binshtein· 3 shared A. Trivette· 2 shared E. Armstrong· 2 shared E. C. Chen· 2 shared E. Davidson· 2 shared J. Rodriguez· 2 shared L. Myers· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

J. E. Crowe

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus

J. E. Crowe, M. Doyle, J. R. Genualdi, A. Bailey, N. Kose, C. Gainza, J. Rodriguez, K. M. Reeder, C. A. Nelson, P. N. Jethva, R. E. Sutton, R. G. Bombardi, M. Gross, J. G. Julander, D. H. Fremont, M. Diamond

The paper isolates a human monoclonal antibody that neutralizes yellow fever virus and provides therapeutic protection in animal models.

bioRxiv · Feb 28, 2022Immunology

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

bioRxiv · Jan 12, 2022 · PreprintImmunology

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

bioRxiv · Jan 12, 2022Immunology

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

J. Dong, S. Zost, A. Greaney, T. N. Starr, A. S. Dingens, E. C. Chen, R. Chen, B. Case, R. Sutton, P. Gilchuk, J. Rodriguez, E. Armstrong, C. Gainza, R. Nargi, E. Binshtein, , J. E. Crowe

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

bioRxiv · Jan 27, 2021 · PreprintImmunology